Ectin Research is active in biotechnology. The company specializes in research and development of drug candidates. The research is focused on developing drugs that aim to eliminate cancerous tumors in patients, with the greatest focus on the treatment of bladder cancer. In addition, the company intends to develop drugs for the treatment of breast, colorectal and prostate cancer cells.

Quotes for Ectin Research AB

Right Now

+/-
-0.14
%
-3,02%
Latest
4.5
High
4.76
Low
4.28
Volume
54 089
Turnover (SEK)
241 160
Value (MSEK)
57,1

Board

CEO

  • Anna Sjöblom-Hallén

Chairperson of the Board

  • Fredrik Sjövall

Board

  • Anders Waas
  • Carlos de Sousa
  • Christer Edlund
  • Fredrik Andersson
  • Marie-Lois Ivarsson
  • Peter Falk

Largest Owners

Name Capital % Votes % Date
Nordnet Pensionsförsäkring 9,08 4,15 2021-12-31
JRS Asset Management AB Client Account 9,05 4,14 2021-12-31
Peter Falk 4,35 19,63 2021-12-31
Ivarsson Medical Research AB 4,33 19,62 2021-12-31
Christer Edlund 4,33 19,62 2021-12-31
Åke Andersson 3,85 1,76 2021-08-03
Power Capital Society AB 3,49 1,60 2021-12-31
Moll Invest AB 3,28 1,50 2021-12-31
Avanza Pension 3,00 1,37 2021-12-31
GU Ventures 2,70 1,23 2021-12-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Upcoming reports

  • 2022-02-22 Bokslutskommuniké 2021

  • 2022-05-17 Delårsrapport 2022-Q1

  • 2022-05-20 Årsstämma 2021

  • 2022-08-23 Delårsrapport 2022-Q2

  • 2022-11-22 Delårsrapport 2022-Q3